Dynacure Receives Fast Track Designation for DYN101, an Investigational Antisense Oligonucleotide for the Treatment of Myotubular and Centronuclear Myopathies Michael Jaramillo2022-01-06T13:09:38-08:00January 6, 2022|
Dynacure to Present at 40th Annual J.P. Morgan Healthcare Conference Michael Jaramillo2022-01-03T13:03:58-08:00January 3, 2022|
